Abstract: The present invention relates to an induced viscosity nutritional emulsion comprising (A) protein having a protein-bound methionine sulfoxide content that is 8% or less of the total protein-bound methionine, on a molar basis, (3} fat, and (C) an induced viscosity fiber system that provides the emulsion with a packaged viscosity of less than 300 cps and an induced viscosity following consumption of at least 300 cps, wherein the induced viscosity nutritional emulsion is an oil-in-water emulsion.
FORM 2
The Patents Act, 1970
(39 of 1970)
&
The Patent Rules, 2003
COMPLETE SPECIFICATION
(See section 10 and rule 13)
"INDUCED-VISCOSITY NUTRITIONAL EMULSIONS"
ABBOTT LABORATORIES, a corporation organized and existing under the laws of State of Illinois, United States of America, having its Registered Office at DEPT.377/AP6A-1, 100 Abbott Park Road, Abbott Park, IL 60064 (US)
The following specification particularly describes the invention and the manner in which it is to be performed
WO 2007-'0-5683
PCT-XTS2006/048430
INDUCED-VISCOSITY NUTRITIONAL EMULSIONS
Technical Field [0001] The present invention relates to induced-viscosity nutritional emulsions having 3 protein component with a defined protein-bound methionine sulfoxide content for improved emulsion stability.
Background of the Invention [0002] There are many different types of nutritional emulsions commercially available or are otherwise disclosed in the literature. These are typically oii-in-water emulsions comprising a balance of fat, protein, carbohydrate, vitamins, and minerals. Some examples include Glucema® and Ensure® brands of packaged nutritional liquids, available from Abbott Laboratories, Columbus, Ohio.
[00 Q3] Recently, a new type of nutritional liquid has been developed that contains, as part of a carbohydrate component, an induced viscosity fiber system. These liquids have a packaged viscosity typical of a nutritional emulsion, but because of the fiber system, result in a higher induced viscosity following consumption. The increased viscosity helps reduce gastric emptying and the subsequent blood glucose response. The viscosity increase within the stomach also provides a sense of fullness and enhanced satiety. These induced viscosity beverages are especially useful in diabetics and in people interested in maintaining or losing weight.
[0004] For example, U.S. Patent Application 20020193344 (Wolf et al.) discloses an induced viscosity beverage, wherein the beverage contains an induced viscosity fiber system having a soluble, anionic fiber in combination with a water insoluble, acid-sotuble cation. The viscosity of the beverage increases following consumption when exposed to the low pH of the stomach.
[0005] In yet another example, U.S. Patent Application 20030013679 (Wolf et al.) discloses an induced viscosity beverage, wherein the beverage comprises a partially hydrolyzed starch in combination with a neutral soluble fiber. The viscosity of the beverage increases following consumption when exposed to acid and amylase in the stomach.
WO 2007/075683
PCT.TS2006/048-130
[OOO5] It has now bean discovered that induced viscosity nutritional emulsions are more prone to creaming and protein sedimentation than conventional emuisions, even as soon as two weeks after formulation, it was aiso been discovered that this inherent instability can be significantly improved by formulating the induced viscosity emulsions with proteins having a protein-bound methionine sulfoxide content that is 8% or less of the total protein-bound methionine, on 3 rnolar basis.
SUMMARY OF THE INVENTION [0007] The present invention is directed to induced viscosity nutritional emulsions comprising (A) protein having a protein-bound methionine sulfoxide (MSO) content that represents 8% or less, on a moiar basis, of the total protein-bound methionine, (b) fat, and (C) an induced viscosity fiber system tn$t provides the emission wi(n a packaged viscosity of less than 300 centipoise (cps) and an induced viscosity following consumption of at least 300 cps. The nutritional emulsions are oiJ-Jn-water emulsions.
[0008] It has been discovered herein that the physical stability of an induced viscosity nutritional emulsion is inversely related to the methionine sulfoxide content of the protein ingredient in the emulsion. More specifically, it has been discovered that an improved physically stable liquid nutritional Product is produced when a protein source with a methionine sulfoxide (MSO) content of 8% or less of the total protein-bound methionine, on a molar basis, is used jn the induced viscosity nutritional emulsion.
DETAILED DESCRIPTION OF THE INVENTION {0009] The induced viscosity nutritional emuisions or the present invention comprise as essential ingredients fat, selected proteins defined by a methionine sulfoxide content, and a carbohydrate component including an induced viscosity fiber system. These and other essential or optional element^ or features of the nutritional emulsions of the present invention are described in detail hereinafter.
[O01O] The term "nutritional emulsion" as used herein, unless otherwise specified, refers to oral liquids in the form of oil-in-water emulsions comprising fat, protein, and carbohydrates, which may be formulated as meal replacement products, nutritional supplements, or continuous (or intermittent) enteral feedings.
2
WO 200^/075633
PCTX"S2006/048430
[0011] The term "induced viscosity nutritional emulsion" as used herein, unless otherwise specified, refers to a nutritional emulsion comprising an induced viscosity fiber system as defined herein.
[0012] The term "induced viscosity fiber system" as used herein, unless otherwise specified, means any fiber-containing material or composition, that when added to a nutritional emulsion allows for a drinkable emulsion viscosity (packaged viscosity) at room temperature and an increased (induced) emulsion viscosity following consumption.
[0013] The nutritional emulsions of the present invention may comprise, consist of, or consist essentity' of the essential element ts and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in a nutritional or pharmaceutical
application.
[0014] All percentages, parts and ratios as used herein are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based upon the active level and, therefore, do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified.
[0015J AH numerical ranges as used herein, whether or not expressly preceded by the term "about", see intended and understood to be preceded by that term, unless otherwise specified.
[0016] All references to singular characteristics or limitations of the present invention shall include the corresponding plural characteristics or limitations, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.
[0017] Aif combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
[0018] The nutritional emulsions of the present invention may also be substantially free of any optional or a selected essential ingredient or feature described herein.
3
WO 200-'0"5683
PCT/CS2006''04S430
provided that the remaining formula stilt contains all of the required ingredients or features as described herein, in this context, the term "substantially free" means that the selected composition contains less than a functional amount of the optional ingredient, typically less than 0.1% by weight, and also including zero percent by weight of such optional or selected essentia) ingredient.
Emulsion Viscosity
[0019] The nutritional emulsicns of the present invention are oil-in-water emulsions that increase in viscosity following consumption, due primarily to the induced viscosity fiber system described hereinafter. These emulsions have a drinkable viscosity prior to consumption, referred to herein as the packaged viscosity, and a higher viscosity following consumption, referred to herein as the induced viscosity.
[0020] The induced viscosity provided by these nutritional emulsions helps reduce gastric emptying and the subsequent blood glucose response. The induced viscosity aiso provides a sense of fullness and enhanced satiety. These induced viscosity nutritional emulsions are especially useful in diabetics and in people interested in maintaining or losing weight.
[0021] As induced viscosity beverages, the nutritional emulsions of the present invention have a drinkable viscosity prior to consumption (i.e., packaged viscosity), which then increases in viscosity following consumption and upon entry into the stomach (i.e., induced viscosity). The viscosity increase arises primarily from the induced viscosity fiber system (described hereinafter) in the nutritional emulsion.
[0022] The nutritional emulsions of the present invention have a packaged viscosity of less than 300 cps, preferably from 40 to 250 cps, more preferably from 40 to 150 cps, including from 75 to 125 cps. In this context, and for purposes of defining the nutritional emulsions of the present invention, a packaged viscosity is measured after removing the emulsion from a sealed package such as from a retort processed or asepticaily filled can, bottle, or other container. Viscosity measurements are taken using a Brookfield (model DVH+) viscometer with a 62 spindle at room temperature. The packaged viscosity is measured by operating the viscometer at a spindle speed that is the highest speed possible to obtain a reading that is on scale
[0023] The nutritional emulsions of the present invention are further defined by an induced viscosity of at least 300 cps, preferably at least 350 cps, including from 400
4
WO 2007/0-5683
PCT.TS2006/048430
to 20,000 cps, and aiso including from about 300 to about 15,000 cps. For an emulsion comprising a polymer controlled induced viscosity fiber system, the induced viscosity is measured by adding 20 pL of bacteria) alpha-amyiase (Sigma) to 250 grams (g) of the emulsion, shearing the enzyme-treated emulsion for 30 minutes using a Glass-Co! mixer, and then measuring viscosity using a Brookfield Viscometer {Model DV-M+) with a 62 spindle at room temperature. The induced viscosity is measured by operating the viscometer at a spindle speed that is the highest speed possible to obtain a reading that is on scaie. This induced viscosity measurement is designed to assimilate the expected induced viscosity for the product following consumption and upon entry into the stomach.
[0024} For emulsions comprising an acid-controlfed induced viscosity fiber system, the induced viscosity is measured by adding 60 ml of 0.1 N HCL solution to 250 grams of the emulsion, shearing the acidified emulsion for 30 minutes using a Glass-, Col mixer, and then measuring the resulting viscosity using a Brookfield (mode) DVH+) viscometer with a 62 spindle at room temperature. The viscosity is measured by operating the viscometer at a spindle speed that is the highest speed possible to obtain a reading that is on scale.
Low MSO Protein
10025] The nutritional emulsions of the present invention comprise a protein source ' having 8% or less, on a molar basis, of the protein-bound methionine as protein-bound methionine sulfoxide, preferably from zero to 5%, including from 1 to 3%.
[0026] The nutritional emulsions are therefore preferably substantially free of any other protein source. In this context, the term "substantially free" means that the nutritional emulsions contains less than 0.5%, more preferably zero percent, by weight, of such other protein source. Such other protein source is one having an MSO content greater than 8%.
[0027] The terms "MSO content", "methionine sulfoxide content" and "protein-bound methionine sulfoxide content" are used interchangeably herein to refer to the amount of protein-bound methionine sulfoxide, as a molar percentage of total protein-bound methionine, of a protein source. MSO content is determined by the analytical methods described herein.
5
WO 200"/0"56SJ
PCTUS20G6r04S43u
[0028] it has been discovered that the induced viscosity nutritional emulsions of the present invention can be formulated with improved stability, and thus increased sheif life, provided that the protein source within the emulsion has a sufficiently low MSO content as defined herein. Improved stability is observed in the form of reduced creaming, reduced protein sedimentation, or both, as measured at 2 weeks, preferably at 6 weeks, mors preferably at S months or longer, after initial forrnuiaticn or packaging.
[0029] it has been discovered that, in preparing protein sources for use in nutritional products, varying amounts of the protein-bound methionine are oxidized to form protein-bound methionine sulfoxide moieties. It has been discovered that induced viscosity nutritions! emulsions are unstable when subsequently formulated with a protein source having an MSO content above 8%, but are stable when the protein source has an MSO content of 8% or less.
[0030] Any protein source suitable for use in a nutritional product is also suitable for use herein, provided that it is processed or otherwise selected to have an MSO content of 3% or less. Suitable proteins sources from which to select or process suitable proteins indude cows milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, com), vegetable (e.g., soy), or combinations thereof.
[0031] Non limiting examples of suitable milk protein sources include milk protein isolates, casein protein isolates, milk protein concentrate, whole cows milk, partially or completely defatted milk, and so forth. Although milk protein isolates are preferred, it is also understood that not al! such isolates will have an MSO content of 8% or less, so not aft such isolates are suitable for use herein. The same is true for other protein sources as well.
[0032] Described below are some commercial protein sources and a corresponding MSO content (measured) for each. Those having an MSO content of 8% or less are suitable for use herein.
Commercial Protein Sources
Supplier Protei ^commodity No.) MSO Content
1 I CaCaseinate <5% - 73%
2 J CaCaseinate <5%
3 C Ca Caseinate^No. 19701 <1%
4 c Na Caseinate (No 198QL <1%
5 D Casein hydrolyzate (No.2216) 5%
6
\VO20-'0G"5683
PCT/US20C'6'048430
8-12%
Whey protein cone. (No. 1332)
7 ! c I Whey protein cone. (No. 15979) i 7-15% i
3 ! G . I Whey protein cone. (R0053 WPC) i 24 - 55% j
9 ] H i Whey Drotein cone. (R006S WPC) ! 4 - 5% I
10 i G I Whey protein cone. (No. 1735) ! 11 - 65% i
11 ! C j Whey protein cone. (No. 18001) i 5% i
12
15%
Soy protein hydrciyzate (No. 3021)
i 13 I A ! Milk protein isolate (No. 15821) 1 8 - 33% I
: 14 i C j Milk protein isolate ! 2 - 5% |
; is ! 3 ; Milk protein isolate 1 2% !
i i6 j j j Whey protein hydrolyzate (IF-3002 WPH)' | 11 - 98% !
17 i | Why protein hyroiyzate (IF-3002 WPH) i 0-21% i
18 C I 1342 } <5% j
19 K ! 1922 ! <5% ;
20 i i Mineral acid casein (No. 1380^ I 1.7 - 2.4% i
21 C J Mineral acid casein (No. 1380) I <1 % I
22 M I Mineral acid casein (No. 1380) ) <1 % |
7
WO 2007/(1-5683
PCT/US2006 04S430
[0033] Described in the following table are commercial nutritional products, each of which contains a protein source with a specified MSO content (as measured from finished product). None of the listed products, however, are induced viscosity emulsions comprising an induced viscosity fiber system.
Commercial Nutritional Products
Product Protei n MSO content
AJimsntum© Abbott Laboratories Casein protein hydrotyzats 4%
Similac© with Iron (powder) Abbott Laboratories Nonfat milk Whey protein cone. 9%
Isomii© Powder Abbott Laboratories Soy protein isolate 5%
Good Start® Powder NesUe Whey protein hydroiyzate 44%
NAN HA1 Powder NesUe Whey protein hydroiyzate 10-11%
Enltve© Liquid Abbott Laboratories Whey protein isolate 23 - 32%
Glucema® Shakes Abbott Laboratories Milk protein isolate 10-40%
Jevity® Nutrition Abbott Laboratories Caselnate <1%
[0034] Since MSO content typically increases during processing, the MSO content for purposes of defining the present invention is preferably measured from finished product, although it is understood that the present invention also includes those finished products wherein the protein source has an MSO content of not more than 8% prior to formulation and processing, unless otherwise specified.
Induced Viscosity Fiber System
[0035] The nutritional emulsions of the present invention comprise an induced
viscosity fiber system, which includes any system that increases the viscosity of the
emulsion following consumption, wherein the packaged viscosity and the induced
viscosity of the emulsions following consumption are within the ranges as defined
herein.
[0036] Any induced viscosity fiber system that is known or otherwise suitable for safe and effective oral administration are suitable for use herein, some examples of which are described in U.S. Patent Applications 20020193344, 20030125301, and 20030013679 (Wolf et al.), which descriptions are incorporated herein by reference.
WO 2007/075683
PCTVUS2006/048430
[0037] Also suitable for use herein are the giucomannan compositions described in U.S. Patent 5,733,769 (Ryan et al.), which descriptions are also incorporated herein by reference.
A) Polymer Controlled Induced Viscosity Fiber System
[0038] The induced viscosity fiber system is preferably a polymer controlled induced viscosity fiber system such as that described in U.S. Patent Application 20030013679, which description is incorporated herein by reference. Such a system comprises a neutrai soluble fiber and a partially hydrolyzed starch having a degree of polymerization (DP) of at least 10.
[0039] The term "neutral water soluble fiber" as used herein refers to those fibers that can be dissolved in water at room temperature &.nd that carry no charge at a neutral pH.
[0040] The nutritional emulsions of the present invention include those embodiments in which the weight ratio of the neutral soluble fiber to the partially hydrolyzed starch in the polymer controlled induced viscosity fiber system ranges from 0.35:5.0 to 1:5.0, including from 0.7:5.0 to 1:5.0, and also including 1:5,0.
[QQ41] Within an emulsion containing the polymer controlled induced viscosity fiber system, the neutral soluble fiber is maintained in a dispersed, insoluble state by the presence of the partially hydrolyzed starch. When two or more polymers such as these are present in the same solution, the solubility of the less soluble polymer (i.e., neutral soiuble fiber) decreases as the concentrationof the more soluble polymer (Le., partially hydrolyzed starch) increases. However, when the partially hydrolyzed starch is digested by alpha amylase in the stomach, its increasing absence within the stomach allows the neutral soluble fiber within the consumed composition to solubilize and thus form a gel and a higher viscosity composition within the stomach. The resulting viscous mass in the stomach delays gastric emptying and slows or delays glucose absorption
[0042] Non limiting examples of neutral soluble fiber-s for use in the polymer controlled induced viscosity fiber system herein include guar gum, pectin, locust bean gum, methyfcellulose, £-giucansr giucomannan, konjac f|our and combinations thereof. Preferred are giucomannan fiber, guar gurr and combinations thereof. The concentration of these neutral soluble fibers are typically at least 0.4%, including
9
WO 20CT/0756S3
PCTTS:0fi6,'O4S430
from 0.55 to 3.0 %, and also including from 0.65 to 1.5%, by weight of the nutritional emulsion.
[0043] Suitable partially hydrolyzed starches for use in this particular induced viscosity fiber system includes those having a DP of at least 10, preferably at least 20, including from 40 to 250, including from 60 to 120, and which are suitable for use in an oral nutritional product. In this context, the degree of polymerization (DP) is the number of glucose or monosaccharide units joined in the molecule. The concentration of the partially hydrolyzed starch is typically at least 2%, including from 3 to 20%, and aiso including from 3.5 to 5%, by weight of the nutritional emulsion
[0044] Non limiting examples of some suitable partially hydrolyzed starches for use herein include those obtained by acid hydrolysis, enzyme hydrolysis, or both. Preferred are those having a DP of from 40 to 250, including DP 100 maltodextrin, and other suitable polysaccharides such as inulin, hydrolyzed guar gum, gum Arabic, and combinations thereof. A DP value is the degree of polymerization of the partially hydrolyzed starch, i.e., the number of monosaccharide units in the partiaiiy hydrolyzed starch.
[0045] The partially hydrolyzed starch may also be characterized in terms of dextrose equivalents (DE) rather than DP values, wherein the partially hydrolyzed starch has a DE of less than 10, including from 1 to 8. A dextrose equivalent (DE) is a conventional measurement representing the average reducing power of maltodextrin or other polysaccharide as compared to a dextrose standard. DE values are derived from the formula [ DE = 100 = DP ], where DP is the degree of polymerization of the maltodextrin or other material, i.e., the number of monosaccharide units in the polysaccharide. For reference, glucose (dextrose) has a DE of 100; starch has a DE of approximately zero.
[0046] The induced viscosity fiber system herein includes those embodiments in which the neutral soluble fiber is glucomannan or konjac flour, and the partially hydrolyzed starch is one having a molecular weight of from 1,000 to 50,000 Daltons.
B) Acid Controlled Induced Viscosity Fiber System 10047] The induced viscosity fiber system for use herein includes acid controlled induced viscosity fiber systems such as those described in U.S. Patent Application 20020193344, which description is incorporated herein by reference.
10
WO :00-'0-56S3
PCTXS2006/04S430
.Such a system comprises a soluble anionic fiber in combination with a water-insoiub)e; acid-soluble, multivalent cation source.
[0048] The term anionic soluble fiber" as used herein refers to water-soluble fibers that carry negative charges after being dissolved in water at room temperature.
[0049] The term water-insoluble, acid-sclubie multivalent cations" refers to salts that are not soluble in water at neutral pH and will react with acid to release the cation. Multivalent cations listed in The Merck Index, Tenth Edition, as insoluble or practically insoluble in water and soluble in acid are examples of suitable salts.
[0050] As part of an acid controlled induced viscosity fiber system, the multivalent cations are insoluble in the nutritional emulsion. Following consumption, and upon entering the stomach, the acid-soluble multivalent cations solubffize and dissociate in the acidic environment of the stomach. The dissociated cations then react with and cross fink the anionic soluble fiber, which then forms a viscous gel or mass in the stomach. The resulting viscous mass delays gastric emptying and slows or delays glucose absorption.
[0051] These acid controlled induced viscosity fiber systems include those embodiments in which the water-in soluble, acid-soluble multivalent cation source represents from 200 to 9000 ppm, including from 300 to 4000 ppm, and also including from 400 to 1000 ppm, by weight of the nutritional emulsion (by weight of the cation).
[0052] Non limiting example of suitable water-insoluble, acid-soluble, multivalent cation sources suitable for use in the induced viscosity fiber system include any water-insoluble, acid-soluble salt of magnesium, calcium, iron, chromium, manganese, molybdenum, copper, or zinc, some examples of which tnciude calcium carbonate, calcium fluoride, calcium molybdate, calcium oxalate, calcium phosphate dibasic, calcium phosphate tribasic, calcium pyrophosphate, calcium saccharate, magnesium fluoride, magnesium hydroxide, magnesium oxide, magnesium peroxide, magnesium phosphate tribasic, magnesium pyrophosphate, magnesium seienite, manganese carbonate, manganese oxide, manganese sulfide and combinations thereof. Calcium carbonate and or calcium triphosphate are preferred.
11
WO 200"'0o6S3
PCTX"S2006'048430
[0053] The nutritional emulsions are therefore preferably substantially free of any water-soluble multivalent cations, or any cations that are otherwise rendered soluble in the finished nutritional product. In this context, the term substantially free means that the nutritional emulsion contains less than 0.2%, preferably zero percent, by weight of a water-sofubfe or product soluble multivalent cation.
[0054] These acid controlled induced viscosity fiber systems include those
5 embodiments in which the soluble anionic fiber represents from 0.2 to 5%, including
form 0.4 to 3%, and also including from 0.8 to 1.5%, by weight of the nutritional emulsion, non-iimtting examples of soluble anionic fibers suitable for use in the induced viscosity fiber system include alginate, low methoxy pectin, carrageenan, xanthan, geilan gum, and combinations thereof. Alginate is preferred.
Macronutrients
[0055] The nutritional emulsions of the present invention comprise fat, protein, and carbohydrate. As described herein, the protein must be a low MSO protein source and the carbohydrate must include an induced viscosity fiber system. The fat component is described hereinafter.
[0056] Although concentrations or amounts of each macronutrient in the nutritional emulsion of the present invention can vary dramatically depending upon the nutritional needs of the intended user, such concentrations or amounts most typicaliy fait within one of the following embodied ranges.
j Macronutrient Embodiments
A B C
i Carbohydrate1 - % total calories 10-85 20-60 40-60
I Fat - % total calories 10-85 10-50 15-35
| Low MSO Protein - % total calories 5-80 10-30 15-25
Carbohydrate1 g/100rn! 1^10 j 4-30 10-20
Fat g/100ml 0.1-30 0.5-15 _j 1-5
1 Low MSO Protein g/100ml | 0.5-30 1-15 2-10
1. Includes induced viscosity fiber system
[0057] The nutritional emulsions of the present invention comprise fat. Suitable fats or sources thereat include any that are known for or otherwise safe for use in oral nutritional products, non limiting examples of which include coconut oil, fractionated coconut oil, soy oil, com oii, olive oil, safflower oii, high oleic saffiower ail, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm
12
wo :oo:-'o:5683
PCTXS2G06/048430
kernel oils, palm oiein, canota oil, marine oils, cottonseed oils, and combinations thereof.
[0058] The nutritional emulsions may comprise, as part of the fat component, polyunsaturated fatty acids, including polyunsaturated fatty acid esters or other natural or synthetic source, including short chain (iess than about 6 carbon atoms per chain), medium chain (from about 6 to 18 carbon atoms per chain) and long chain (having at least about 20 carbon atoms per chain) fatty acids having two or more carbon:csrbon doubie bonds, including n-3 (omega-3) and n-6 (omega-6) polyunsaturated fatty acids.
[0059] Non limiting examples of polyunsaturated fatty acids suitable for use herein include afpha-linotenic acid (ALA, C18:3n-3), stearidonic acid (C18:4n-3), eicosapentaenoic acid (EPA, C2G:5n-3), docosapentaenoic acid (C22:5n-3), docosahexaenotc acid (DHA, C22:6n-3), linoleic acid (C18:2n-6), gamma-linolenic acid (GLA, C18;3n-6), eicosadienoic acid (C20:2n-6)t arachidonic acid {ARA, C20:4n-6), di-homo-gamma-iinolentc acid (DGI-A, C20;3n-6), and combinations thereof.
[0060] The nutritional emulsions of the present invention may further comprise a carbohydrate in addition to that provided by the induced viscosity fiber system described herein. Non limiting examples of such additional carbohydrates include additional hydrolyzed or modified starch or cornstarch, glucose polymers, com syrup, com syrup solids, rice-derived carbohydrate, glucose, fructose, lactose, high fructose corn syrup, indigestible oligosaccharides (e.g., fructooligosaccharides), honey, sugar alcohols (e.g., maltitol, erythrltoi, sorbitol), and combinations thereof.
[0061] The nutritional emulsions of the present invention may further comprise any other nutrient, excipient, or other additive, provided that such optional ingredients are safe for use in an oral nutritional and do not unduly affect product performance. Vitamins and minerals are preferred in this regard.
MSO Method
[0062] The methionine sulfoxide (MSO) content of the protein source for use herein is determined in accordance with the following method. For proper protein selection, the potential protein source is subjected to enzymatic hydrolysis at 37*C for 24 hours. The resulting enzyme digest is then evaluated for MSO and methionine content by
13
wo :oD_;o"56Sj
PCT/L"S:O0ti.Ti4S43
reversed phase HPLC. The percentage of MSO in the protein source is then determined as follows:
.rPirotein-bound MSO, as moie % of total protein-bound methionine = "MSO X 100
'; (MSO + MET)
i MSO = methionine sulfoxide in molar units
jJyiET = methionine in same molar units
[0063] As an example of the above method, a protein source (calcium caseinate and sodium caseinate) is evaluated as follows:
A. Standard Preparation
a. Dissolve 100 mg of (.-methionine and 50 mg of DL-methfonfne
suifoxide (Fiuka 64430) in 1000 mL of water. This is the High
standard solution.
b. Dilute 25.0 ml_ of high standard solution to 50 rnL with water. This is
the low standard solution,
B. Sample Preparation
a. Dissolve 90-95 mg of caseinate ingredient in 25 mL of 0.05M PIPES,
pH 7.5, containing 0.1% sodium azide.
b. Pipet 3.00 mL of the caseinate solution into a 1-dram vial.
c. Add 150 uL of pronase (Sigma P-5147), 2 mg/mL in 0.05M PIPES, pH
7.5, containing 0.1% sodium azide.
d. Add 60 uL of leucine aminopeptidase (Sigma L-0632), 2 mg/mL in
water.
e. Add 30 pL of prolidase (Sigma P-6675), 2 mg/mL in water.
f. Cap viai and gentiy mix. Dispense 1600 {it into each of two crirnp-
seal HPLC autosampter vials (VWR 66020-953), and seal the vials.
g. mcubate at 37'C for 24 hours.
h. Test for MSO and for MET by the HPLC system described beiow.
C. HPLC System
Column: ODS-AQ, 4.6 x 250 mm, 5pm, 12OA, Waters AQ12S052546WT
Mobile Phase A: Water
Mobife Phase B: 350 mL 0.02 KH2PO4, pH 2.9; 650 mL acetonitrile
Temperature: 40"C
Detection: UV at 221 ran, 214 nm
Injection: 1 uL
Efution Program: See tabfe in Appendix A under "C. HPLC System"
14
WO 2007/0756S3
PCT/CS2006/048430
Protein Samples
[0084} MSO content of various commercial protein sources is measured and compared. The different protein sources are then evaluated for physical stability in an induced viscosity nutritional emulsion.
[0065] Of the nine protein sources tested, those having an MSO content of not mere than 5% showed good emulsion stability, while those with an MSO content of less than 3% showed only fair or poor stability. These results illustrate the inversely proportional relationship between MSO content and HPLC Peak Height and between MSO content and induced viscosity emulsion stability. The data from the tests are summarized in the following table.
Milk Protein isolate' Source code
C 09 MSO Content
2.8% HPLC Peak" Height
As mAU/gat214
nm Induced viscosity emulsion stability 55*C at 2 weeks '
1
2381 Good
2 C 15 2.9% 2488 Good
3 C 16 2.8% 2397 Good
4 C 18 2.5% 2390 Good
5 C08 1.8% 2325 ND
6 B04 2.1% ND Good
7 A 59 8% 20U Good
8 A04 13% 1822 Fair
9 A17 33% 1344 Poor
EXAMPLES
[0056] The following examples illustrate specific embodiments of the nutritional emulsions of the present invention, including suitable techniques to prepare the emulsions. The examples are given solely for the purpose of illustration and are not to'^be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.
Example 1
15
[00672 The following is an induced viscosity nutritional emulsion of the present invention and a process for making it. This embodiment contains a polymer controlled induced viscosity fiber system in combination with a protein having an MSO content in finished product of from 1-3%.
WO 2007.-0-5683
PCT-TS2006'048430
j Canola oil i 13.7 kp | Msltodextrin DPT 00 45.3 ka !
/ Soy lecithin f 0.7 kg f Fructose 28 kp /
Vitamin OBK premix | 47.3 a I j Nlicronized tricalcium 0.9 kg ]
Beta carotene 30% ! 6.5 g J Magnesium chloride 0.4 kg Vitamin A palmiiate !4.6g ( Sodium citrate 2.4 ka ;
Lutein ' 4.9 g 1 Fructooiigosaccharides 12.S ka i
Vitamin E i 71.9 g (_K phosphate dibasic 0.35 kg_
Konjac powder 1 5.57 kg | Maitodextrin DP 5 21.1 kg ;
3.33 kc
393 Kg
37.2 kg
3.24 ka
_343_g_
Guar gum
Water
Milk Protein Isolate
Sodium caseinate
Low viscosity Sodium 5.7 kg Casemate
Vatamin^
Water j 39 kg
425 g
Ascorbic acid
Choline chloride
MaUitol syrup (70% solids) j 34.3 kg
1.2 kc
Potassium Chloride
0.8 ka
I Calcium carbonate
0.2 kg
Gellan gum
3.1 kg
Mo phosphate dibasic
550 g
I Potassium citrate
270 g
I Ultra/trace mineral premix
0.1fifl
Potassium iodide
1.6g
Chromium chloride
Water sol, vitamin premix J70.9 g
300 g
Sucralose
{ 1.5 kg
Vanilla flavor
[0058] In preparing this nutritional emulsion (-1000 kg), the fat blend is formed separately by combining the specified ingredients. The protein-in-water slurry is also prepared separately by combining the specified ingredients. The carbohydrate/mineral slurry is likewise formed as a separate mixture by combining the specified ingredients.
[0069] The carbohydrate/mineral slurry is then added to the protein-in-water slurry and the blend pH adjusted to 6.7-7.0. To the resulting blend is added the fat blend. The mixture thus formed is then processed at UHT temperatures (295°F for 5 seconds) and homogenized at 4000 psi. The ingredients for the vitamin solution are then combined and the pH adjusted to 6.5-7.5 using 45% KOH. The vitamin solution is then added to the homogenized blend at standardization. The final blend is then packaged ancf sealed in individual 8 oz. containers and subjected to retort.
[0070] The resulting product has a packaged viscosity of 120 cps and an induced viscosity of over 14,000 cps (upon treatment with alpha amylase). The product remains stable without significant creaming or protein sedimentation at 2 weeks, 6 months, and 12 months.
Example 2
16
\\0 :oo".'o:56S3
PCTTS2006/C4S430
[0071] The following is an induced viscosity nutritional emulsion of the present invention and a process for making it This embodiment contains a polymer controlled induced viscosity fiber system in combination with a protein having an MSO content in finished product of from 1-3%.
Ingredients - Example 2
5.57 kg
3.33 kg
30.6 kg
Diacyiglycerol oil 17.7 kg
9.4 kg
High oleic safflower oil
1.5 kg
Canoia oil
0.6 kg
Soy lecithin
4T.3g
Vitamin DEK preroix
4.6 g
Vitamin A palmitate
71.9 g
Vitamin E
_Konjac powder
guar gum_
398 kg
Water
Milk protein isolate
10 kg
5.7 kg
Sodium casemate Low viscosity sodium caseinate
Water
Maltodextrin DP100
Fructose
Micronized tricaicium
phosphate
Magnesium Chioride
Sodium citrate
Fnuctooiigosaccharides
K phosphate dibasic
Maltodextrin DP 5
Maltitol syrup (70 %)
Potassium Chloride
Calcium carbonate
Gellan gum
Microcrystalline cellulose
Mg phosphate dibasic Potassium citrate
Ultra/trace mineral premix
Potassium iodide
Chromium chloride
341 kg
45.3 kg
28 kg
0.9 kg
0.4 kg
2.4 kg
12.6 kg
0.35 kg
21.1 kg
34.3 kg
1.2 kg
0.8 kg
0.2 kg
0.6 kg_
3.1 kg 550 g
270_g_
0.16 g
1.6g
17
WO 2007;
| Section | Controller | Decision Date |
|---|---|---|
| 15 | Bharat N S | 2014-06-13 |
| 15 | Bharat N S | 2014-06-13 |
| # | Name | Date |
|---|---|---|
| 1 | 1373-MUMNP-2008-CLAIM(GRANTED)-(13-6-2014).pdf | 2018-08-09 |
| 1 | 1373-MUMNP-2008-CORRESPONDENCE(17-10-2013).pdf | 2013-10-17 |
| 2 | 1373-MUMNP-2008-CLAIMS(AMENDED)-(3-10-2011).pdf | 2018-08-09 |
| 2 | 1373-MUMNP-2008-CORRESPONDENCE(31-10-2013).pdf | 2013-10-31 |
| 3 | Form 27 [29-03-2016(online)].pdf | 2016-03-29 |
| 3 | 1373-MUMNP-2008-CLAIMS(AMENDED)-(5-12-2013).pdf | 2018-08-09 |
| 4 | ipindiaonline.gov.in_epatentfiling_online_frmPreview.asp.pdf | 2018-08-09 |
| 4 | 1373-MUMNP-2008-CLAIMS(MARKED COPY)-(5-12-2013).pdf | 2018-08-09 |
| 5 | 1373-MUMNP-2008_EXAMREPORT.pdf | 2018-08-09 |
| 5 | 1373-mumnp-2008-claims.doc | 2018-08-09 |
| 6 | 1373-MUMNP-2008-SPECIFICATION(AMENDED)-(3-10-2011).pdf | 2018-08-09 |
| 6 | 1373-mumnp-2008-claims.pdf | 2018-08-09 |
| 7 | 1373-MUMNP-2008-REPLY TO HEARING(5-12-2013).pdf | 2018-08-09 |
| 7 | 1373-MUMNP-2008-CORRESPONDENCE(10-3-2014).pdf | 2018-08-09 |
| 8 | 1373-MUMNP-2008-REPLY TO EXAMINATION REPORT(3-10-2011).pdf | 2018-08-09 |
| 8 | 1373-MUMNP-2008-CORRESPONDENCE(21-3-2011).pdf | 2018-08-09 |
| 9 | 1373-MUMNP-2008-CORRESPONDENCE(21-4-2011).pdf | 2018-08-09 |
| 9 | 1373-MUMNP-2008-REPLY TO EXAMINATION REPORT(21-4-2011).pdf | 2018-08-09 |
| 10 | 1373-MUMNP-2008-CORRESPONDENCE(4-3-2014).pdf | 2018-08-09 |
| 10 | 1373-mumnp-2008-power of attprney.pdf | 2018-08-09 |
| 11 | 1373-MUMNP-2008-CORRESPONDENCE(6-2-2012).pdf | 2018-08-09 |
| 11 | 1373-MUMNP-2008-PETITION FOR CONDONATION DELAY-(5-12-2013).pdf | 2018-08-09 |
| 12 | 1373-MUMNP-2008-CORRESPONDENCE(8-11-2011).pdf | 2018-08-09 |
| 12 | 1373-MUMNP-2008-PETITION FOR CONDONATION DELAY(5-12-2013).pdf | 2018-08-09 |
| 13 | 1373-MUMNP-2008-CORRESPONDENCE(9-9-2008).pdf | 2018-08-09 |
| 13 | 1373-mumnp-2008-pct-isa-237.pdf | 2018-08-09 |
| 14 | 1373-MUMNP-2008-CORRESPONDENCE(IPO)-(11-7-2014).pdf | 2018-08-09 |
| 14 | 1373-MUMNP-2008-PCT-ISA-237(9-9-2008).pdf | 2018-08-09 |
| 15 | 1373-mumnp-2008-correspondence.pdf | 2018-08-09 |
| 15 | 1373-mumnp-2008-pct-isa-220.pdf | 2018-08-09 |
| 16 | 1373-MUMNP-2008-DECRIPTION(GRANTED)-(13-6-2014).pdf | 2018-08-09 |
| 16 | 1373-mumnp-2008-pct-isa-210.pdf | 2018-08-09 |
| 17 | 1373-MUMNP-2008-PCT-IB-326(9-9-2008).pdf | 2018-08-09 |
| 18 | 1373-mumnp-2008-pct-ib-308.pdf | 2018-08-09 |
| 18 | 1373-mumnp-2008-description(complete).pdf | 2018-08-09 |
| 19 | 1373-MUMNP-2008-FORM 1(21-3-2011).pdf | 2018-08-09 |
| 19 | 1373-mumnp-2008-pct-ib-304.pdf | 2018-08-09 |
| 20 | 1373-mumnp-2008-form 1.pdf | 2018-08-09 |
| 20 | 1373-mumnp-2008-pct requst form.pdf | 2018-08-09 |
| 21 | 1373-mumnp-2008-form 13(21-3-2011).pdf | 2018-08-09 |
| 21 | 1373-mumnp-2008-isa 213.pdf | 2018-08-09 |
| 22 | 1373-mumnp-2008-form 18.pdf | 2018-08-09 |
| 22 | 1373-mumnp-2008-international publication report-wo.pdf | 2018-08-09 |
| 23 | 1373-MUMNP-2008-FORM 2(GRANTED)-(13-6-2014).pdf | 2018-08-09 |
| 23 | 1373-MUMNP-2008-GENERAL POWER OF ATTORNEY(21-3-2011).pdf | 2018-08-09 |
| 24 | 1373-MUMNP-2008-FORM PCT-ISA-237(21-4-2011).pdf | 2018-08-09 |
| 24 | 1373-MUMNP-2008-FORM 2(TITLE PAGE)-(GRANTED)-(13-6-2014).pdf | 2018-08-09 |
| 25 | 1373-mumnp-2008-form 2(title page).pdf | 2018-08-09 |
| 25 | 1373-MUMNP-2008-FORM PCT-IB-373(21-4-2011).pdf | 2018-08-09 |
| 26 | 1373-mumnp-2008-form 5.pdf | 2018-08-09 |
| 27 | 1373-mumnp-2008-form 2.pdf | 2018-08-09 |
| 27 | 1373-MUMNP-2008-FORM 3(5-12-2013).pdf | 2018-08-09 |
| 28 | 1373-MUMNP-2008-FORM 3(21-4-2011).pdf | 2018-08-09 |
| 28 | 1373-MUMNP-2008-FORM 3(4-3-2014).pdf | 2018-08-09 |
| 29 | 1373-MUMNP-2008-FORM 3(21-4-2011).pdf | 2018-08-09 |
| 29 | 1373-MUMNP-2008-FORM 3(4-3-2014).pdf | 2018-08-09 |
| 30 | 1373-mumnp-2008-form 2.pdf | 2018-08-09 |
| 30 | 1373-MUMNP-2008-FORM 3(5-12-2013).pdf | 2018-08-09 |
| 31 | 1373-mumnp-2008-form 5.pdf | 2018-08-09 |
| 32 | 1373-mumnp-2008-form 2(title page).pdf | 2018-08-09 |
| 32 | 1373-MUMNP-2008-FORM PCT-IB-373(21-4-2011).pdf | 2018-08-09 |
| 33 | 1373-MUMNP-2008-FORM 2(TITLE PAGE)-(GRANTED)-(13-6-2014).pdf | 2018-08-09 |
| 33 | 1373-MUMNP-2008-FORM PCT-ISA-237(21-4-2011).pdf | 2018-08-09 |
| 34 | 1373-MUMNP-2008-FORM 2(GRANTED)-(13-6-2014).pdf | 2018-08-09 |
| 34 | 1373-MUMNP-2008-GENERAL POWER OF ATTORNEY(21-3-2011).pdf | 2018-08-09 |
| 35 | 1373-mumnp-2008-form 18.pdf | 2018-08-09 |
| 35 | 1373-mumnp-2008-international publication report-wo.pdf | 2018-08-09 |
| 36 | 1373-mumnp-2008-form 13(21-3-2011).pdf | 2018-08-09 |
| 36 | 1373-mumnp-2008-isa 213.pdf | 2018-08-09 |
| 37 | 1373-mumnp-2008-pct requst form.pdf | 2018-08-09 |
| 37 | 1373-mumnp-2008-form 1.pdf | 2018-08-09 |
| 38 | 1373-MUMNP-2008-FORM 1(21-3-2011).pdf | 2018-08-09 |
| 38 | 1373-mumnp-2008-pct-ib-304.pdf | 2018-08-09 |
| 39 | 1373-mumnp-2008-description(complete).pdf | 2018-08-09 |
| 39 | 1373-mumnp-2008-pct-ib-308.pdf | 2018-08-09 |
| 40 | 1373-MUMNP-2008-PCT-IB-326(9-9-2008).pdf | 2018-08-09 |
| 41 | 1373-MUMNP-2008-DECRIPTION(GRANTED)-(13-6-2014).pdf | 2018-08-09 |
| 41 | 1373-mumnp-2008-pct-isa-210.pdf | 2018-08-09 |
| 42 | 1373-mumnp-2008-correspondence.pdf | 2018-08-09 |
| 42 | 1373-mumnp-2008-pct-isa-220.pdf | 2018-08-09 |
| 43 | 1373-MUMNP-2008-CORRESPONDENCE(IPO)-(11-7-2014).pdf | 2018-08-09 |
| 43 | 1373-MUMNP-2008-PCT-ISA-237(9-9-2008).pdf | 2018-08-09 |
| 44 | 1373-MUMNP-2008-CORRESPONDENCE(9-9-2008).pdf | 2018-08-09 |
| 44 | 1373-mumnp-2008-pct-isa-237.pdf | 2018-08-09 |
| 45 | 1373-MUMNP-2008-CORRESPONDENCE(8-11-2011).pdf | 2018-08-09 |
| 45 | 1373-MUMNP-2008-PETITION FOR CONDONATION DELAY(5-12-2013).pdf | 2018-08-09 |
| 46 | 1373-MUMNP-2008-CORRESPONDENCE(6-2-2012).pdf | 2018-08-09 |
| 46 | 1373-MUMNP-2008-PETITION FOR CONDONATION DELAY-(5-12-2013).pdf | 2018-08-09 |
| 47 | 1373-mumnp-2008-power of attprney.pdf | 2018-08-09 |
| 47 | 1373-MUMNP-2008-CORRESPONDENCE(4-3-2014).pdf | 2018-08-09 |
| 48 | 1373-MUMNP-2008-REPLY TO EXAMINATION REPORT(21-4-2011).pdf | 2018-08-09 |
| 48 | 1373-MUMNP-2008-CORRESPONDENCE(21-4-2011).pdf | 2018-08-09 |
| 49 | 1373-MUMNP-2008-CORRESPONDENCE(21-3-2011).pdf | 2018-08-09 |
| 49 | 1373-MUMNP-2008-REPLY TO EXAMINATION REPORT(3-10-2011).pdf | 2018-08-09 |
| 50 | 1373-MUMNP-2008-CORRESPONDENCE(10-3-2014).pdf | 2018-08-09 |
| 50 | 1373-MUMNP-2008-REPLY TO HEARING(5-12-2013).pdf | 2018-08-09 |
| 51 | 1373-mumnp-2008-claims.pdf | 2018-08-09 |
| 51 | 1373-MUMNP-2008-SPECIFICATION(AMENDED)-(3-10-2011).pdf | 2018-08-09 |
| 52 | 1373-MUMNP-2008_EXAMREPORT.pdf | 2018-08-09 |
| 53 | ipindiaonline.gov.in_epatentfiling_online_frmPreview.asp.pdf | 2018-08-09 |
| 53 | 1373-MUMNP-2008-CLAIMS(MARKED COPY)-(5-12-2013).pdf | 2018-08-09 |
| 54 | Form 27 [29-03-2016(online)].pdf | 2016-03-29 |
| 54 | 1373-MUMNP-2008-CLAIMS(AMENDED)-(5-12-2013).pdf | 2018-08-09 |
| 55 | 1373-MUMNP-2008-CORRESPONDENCE(31-10-2013).pdf | 2013-10-31 |
| 55 | 1373-MUMNP-2008-CLAIMS(AMENDED)-(3-10-2011).pdf | 2018-08-09 |
| 56 | 1373-MUMNP-2008-CORRESPONDENCE(17-10-2013).pdf | 2013-10-17 |
| 56 | 1373-MUMNP-2008-CLAIM(GRANTED)-(13-6-2014).pdf | 2018-08-09 |